Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program

Raushan T. Kurmasheva; C. Patrick Reynolds; Min H. Kang; Cecilia Allievi; Peter J. Houghton; Malcolm A. Smith

doi:10.1002/pbc.24800

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program

Raushan T. Kurmasheva, C. Patrick Reynolds, Min H. Kang, Cecilia Allievi, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0nM to 30.0μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5mg/kg) administered intravenously using an every 4 day×3 schedule. In vitro pixantrone showed a median relative IC₅₀ value of 54nM (range <3nM to 1.03μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft. Pediatr Blood Cancer 2014;61:922-924.

Original language	English (US)
Pages (from-to)	922-924
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	61
Issue number	5
DOIs	https://doi.org/10.1002/pbc.24800
State	Published - May 2014
Externally published	Yes

Keywords

Developmental therapeutics
Preclinical testing
Topoisomerase 2 inhibitor

ASJC Scopus subject areas

Hematology
Oncology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1002/pbc.24800

Cite this

@article{9a847873e3f449d3a0b28db5af3bfd9e,

title = "Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program",

abstract = "Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0nM to 30.0μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5mg/kg) administered intravenously using an every 4 day×3 schedule. In vitro pixantrone showed a median relative IC50 value of 54nM (range <3nM to 1.03μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft. Pediatr Blood Cancer 2014;61:922-924.",

keywords = "Developmental therapeutics, Preclinical testing, Topoisomerase 2 inhibitor",

author = "Kurmasheva, {Raushan T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Cecilia Allievi and Houghton, {Peter J.} and Smith, {Malcolm A.}",

year = "2014",

month = may,

doi = "10.1002/pbc.24800",

language = "English (US)",

volume = "61",

pages = "922--924",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program

AU - Kurmasheva, Raushan T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Allievi, Cecilia

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

PY - 2014/5

Y1 - 2014/5

N2 - Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0nM to 30.0μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5mg/kg) administered intravenously using an every 4 day×3 schedule. In vitro pixantrone showed a median relative IC50 value of 54nM (range <3nM to 1.03μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft. Pediatr Blood Cancer 2014;61:922-924.

AB - Pixantrone, a novel aza-anthracenedione with cytotoxic activity, was tested against the PPTP in vitro panel (3.0nM to 30.0μM) and against a limited panel of PPTP Wilms tumors and sarcomas (7.5mg/kg) administered intravenously using an every 4 day×3 schedule. In vitro pixantrone showed a median relative IC50 value of 54nM (range <3nM to 1.03μM). In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. A complete response was observed for one Wilms tumor xenograft. Pediatr Blood Cancer 2014;61:922-924.

KW - Developmental therapeutics

KW - Preclinical testing

KW - Topoisomerase 2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84895736539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895736539&partnerID=8YFLogxK

U2 - 10.1002/pbc.24800

DO - 10.1002/pbc.24800

M3 - Article

C2 - 24166988

AN - SCOPUS:84895736539

SN - 1545-5009

VL - 61

SP - 922

EP - 924

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 5

ER -

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this